HTG Molecular Appoints New Vice President of North American Capital Sales for the HTG EdgeSeq Platform

June 20, 2016 at 4:01 PM EDT

TUCSON, Ariz., June 20, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for NGS-based molecular profiling applications, today announced the appointment of Suzanne Hill as Vice President of North American Capital Sales.

In this role, Ms. Hill will be responsible for leading the sales team in the commercialization of the
HTG EdgeSeq system and associated reagents in North America. Ms. Hill brings proven capital sales leadership in life science tools to the HTG business team with an extensive background in sequencing and genomics. Prior to joining HTG, Ms. Hill served as Director of Sales at Silicon Biosystems in San Diego, CA. Earlier in her career, she held a number of commercial positions of increasing responsibility at Illumina, Inc. Prior to her seven years at Illumina, Ms. Hill was the Director of Sales for North America at CryoXtract, the Mid Atlantic Regional Sales Manager at Leica, and Regional and Global Account Executive at Perkin Elmer and Roche. 

“We are delighted to be able to recruit someone of Suzanne’s background and experience,” stated TJ Johnson, Chief Executive Officer and President of HTG. “Ms. Hill’s genomics sales leadership, especially her seven years at Illumina during their initial commercial ramp up phase, will be extremely helpful as we accelerate the commercialization of HTG’s instrument platform.”

Ms. Hill earned a B.S. in biology and plant genetics from Penn State University.

About HTG:

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with our newly hired employee and her expected benefits to us; and our business and the rate of commercialization of our technology. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with our ability to successfully develop markets for our products, and our ability to successfully develop and commercialize our products. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including, without limitation, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Westwicke PartnersJamar Ismail
Phone: 415-513-1282

TJ Johnson President / CEO
HTG Molecular Diagnostics Phone: 520-547-2827 x130

Primary Logo

HTG Molecular Diagnostics, Inc.